drugset / Trial / NCT04031755

A Proof-of-Concept Study of Minocycline in Autism

NCT04031755

Phase 1 Completed 53 enrolled Children's Hospital Medical Center, Cincinnati
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of the study is to determine if Minocycline shows initial evidence of efficacy, safety, and tolerability in youth with Autism Spectrum Disorder ages 12 to 22 years.

Timeline

Start
2019-04-19
Primary completion
2020-10-30
Completion
2020-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Minocycline Small molecule 100 mg

Indications